Form 13-F position report

GRAPHITE BIO INC

Reported by MORGAN STANLEY

GRPH CUSIP 38870X104 Manager CIK 0000895421

Reported 31,323 shares, down 688,831 (95.7%) from the prior quarter.

Reported value -94.9%; share count -95.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2022
Shares 31,323 Quarter-end amount reported
Reported value $100,000 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 8680000
2022-03-31 2869000
2022-06-30 1980000
2022-09-30 100000
2022-12-31 117190
2023-03-31 500583
2023-06-30 186992
2023-09-30 361988
2023-12-31 536520
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for GRAPHITE BIO INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -204,778 (-100.0%) 0 $0 2024-05-15
Q4 2023 Added 204,778 +58,815 (40.3%) < 0.01% $536,520 2024-02-13
Q3 2023 Added 145,963 +74,043 (103.0%) < 0.01% $361,988 2023-11-15
Q2 2023 Reduced 71,920 -132,400 (-64.8%) < 0.01% $186,992 2023-08-14
Q1 2023 Added 204,320 +169,022 (478.8%) < 0.01% $500,583 2023-05-15
Q4 2022 Added 35,298 +3,975 (12.7%) < 0.01% $117,190 2023-02-14
Q3 2022 Reduced 31,323 -688,831 (-95.7%) < 0.01% $100,000 2022-11-14
Q2 2022 Added 720,154 +157,660 (28.0%) < 0.01% $1,980,000 2022-08-15
Q1 2022 Reduced 562,494 -135,886 (-19.5%) < 0.01% $2,869,000 2022-05-13
Q4 2021 Added 698,380 +284,615 (68.8%) < 0.01% $8,680,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

76 managers reported GRAPHITE BIO INC for Q3 2022.

Managers reporting GRAPHITE BIO INC in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Samsara BioCapital LLC Unchanged 8,459,314 0 6.25% $26,816,000 6 qtrs
FMR LLC Reduced 4,872,758 -354,702 < 0.01% $15,446,643 6 qtrs
EcoR1 Capital LLC Added 1,582,135 +419,956 0.15% $5,015,000 4 qtrs
Avidity Partners Management LP Added 1,575,000 +865,000 0.1% $4,993,000 6 qtrs
CITADEL ADVISORS LLC Reduced 1,274,047 -45,789 < 0.01% $4,039,000 6 qtrs
VANGUARD GROUP INC Added 1,200,282 +136,371 < 0.01% $3,805,000 6 qtrs
TANG CAPITAL MANAGEMENT LLC Unchanged 1,100,000 0 0.43% $3,487,000 2 qtrs
FEDERATED HERMES INC Added 1,057,983 +1,675 < 0.01% $3,353,000 6 qtrs
ORBIMED ADVISORS LLC Unchanged 848,412 0 0.05% $2,689,000 6 qtrs
Board of Trustees of The Leland Stanford Junior University Unchanged 703,071 0 0.14% $2,229,000 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 14, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
23,423
Shared
0
None
7,900

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.